
Ruilongnuofu Medical Technology
Developing MIS and digital surgery solutions.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
investor investor investor investor investor | €0.0 | round | |
investor investor investor investor investor investor investor | €0.0 | round | |
* | CNY300m | Series B | |
Total Funding | 000k |
Related Content
Shanghai-based Ronovo Surgical, operating under the full name Shanghai Ruilongnuofu Medical Technology Co., Ltd., was established in 2019 by co-founders John Ma and Dr. Ying Mao. John Ma, the company's CEO, brings extensive experience from the medical device industry, having held senior positions at Fosun Pharma and Intuitive Surgical. Dr. Ying Mao, the Chief Medical Officer, is a distinguished neurosurgeon and serves as the honorary president of Huashan Hospital, a prominent institution affiliated with Fudan University. This blend of commercial and clinical expertise has shaped the company's strategic direction.
Ronovo Surgical has positioned itself in the rapidly expanding market for robotic-assisted surgery, with an initial focus on mainland China. The company addresses the demand for advanced, yet more accessible, minimally invasive surgical options. Its business model centers on the development and sale of a proprietary surgical robotics platform, targeting hospitals and surgical centers. The primary revenue stream is expected from the sale of the Carina™ system and recurring sales of compatible surgical instruments and accessories.
The cornerstone of their offering is the Carina™ robotic surgical platform, a modular system designed for versatility in various soft tissue surgeries. This platform is composed of several key components: a primary laparoscopic surgical system, an advanced high-definition imaging system providing functional vision, and a comprehensive set of surgical instruments and accessories. A notable feature is its modularity, which allows for greater flexibility and adaptability in the operating room compared to single-unit systems. The system has successfully completed multi-center clinical trials in specialties such as gynecology and urology, leading to its clearance by China's National Medical Products Administration (NMPA) in early 2024.
Keywords: surgical robotics, medtech, minimally invasive surgery, Carina platform, NMPA approved, modular robotics, soft tissue surgery, medical devices, laparoscopy, healthcare technology